We have all had the encounter. The patient who is "certain" they need an antibiotic. "I've had this before." "It always turns into something." "I always need one eventually." "The last time I didn't get one I ended up in the ER."
Join the Movement
Your doctor should be getting this right. Now you'll know when they're not.
What they are describing is not clinical knowledge. It is a pattern reinforced over years of inadvertent conditioning — and we, as prescribers, are the primary mechanism of that conditioning.
The mechanism.
Viral upper respiratory infections tend to follow a predictable symptom arc — escalation, plateau, and recovery. This arc is largely immune-mediated and self-limiting in the immunocompetent adult.
Patients often present at a distressing part of the curve — when symptoms have stalled and mucus has thickened. This is precisely the inflection point at which natural recovery is imminent. An antibiotic prescribed at that moment will be associated with improvement in virtually every case. Not because the antibiotic accelerated resolution, but because resolution was forthcoming regardless.
The antibiotic addresses the patient's need — not pharmacologically, but psychologically. Many patients report feeling better the moment they swallow the pill. That relief is real. It is just not coming from the antibiotic. It is coming from the act of having a plan, from the reduction of uncertainty. When improvement then follows, as it always was going to, the antibiotic gets the credit.
This is not patient irrationality. It is a logical inference from incomplete information — incomplete information we are in a position to correct.
The prescriber side of the cycle.
The pressure to prescribe in this encounter is real, and it would be intellectually dishonest to pretend otherwise. Time constraints, patient satisfaction metrics, the path of least resistance, and the patient who has been through this enough times to make a confident case — these are not trivial forces.
Clinical inertia in this context is not laziness. It is rational behavior under pressure. Prescribing takes 30 seconds. The conversation that might prevent it takes 5 minutes the clinician often does not have. The cost of that transaction is deferred and diffuse. Someone else pays it — the patient who returns next cold season certain they need another antibiotic. The patient who develops C. diff. The clinician inheriting a resistant organism with no good options.
Recognizing this dynamic is not self-indulgent reflection. It is prerequisite to changing it.
What the data actually say.
Controlling Evidence — 2025 Cochrane Review (Kenealy & Arroll, CD000247)
Antibiotics for the common cold showed NO evidence of benefit vs. placebo. No improvement in cure rates or symptom duration. RR 0.83 (95% CI 0.60–1.14). The NNT is effectively incalculable — there is no demonstrated therapeutic benefit to calculate against.
NNH — Real and Measurable
Overall RR for adverse effects: 1.8 (95% CI 1.01–3.21). In adults specifically: RR 2.62 (95% CI 1.32–5.18). NNH for any adverse event in adults: approximately 6–10. Adverse events include GI symptoms, rash, allergic reactions, C. diff (HR 2.90, Butler et al., Clin Infect Dis 2023), and increased healthcare expenditures of $18–$67 per patient.
The conversation is not about whether antibiotics are effective drugs. They are. The conversation is about whether the documented benefit in this indication outweighs the documented harm. There is no benefit side of the equation. The harm is real, frequent, and measurable.
We created this belief cycle — one prescription at a time. We are the only ones who can break it.
A framework for the encounter.
The most effective time to build the case is during the exam — not at the conclusion when the patient is already anticipating a prescription. Framing antibiotic stewardship as the clinical reasoning, not the refusal, changes the encounter.
Preserve dignity: "As I am sure you are aware, most of what we're dealing with here is viral." This positions the patient as a peer in the reasoning, not a subject of correction.
Name the mechanism: Explain the plateau-to-recovery arc directly. Most patients have never had the timeline explained to them. Understanding it reframes their past experiences.
Acknowledge the pressure: "I know it feels like it always turns into something — let me show you what the exam actually tells us." Affect labeling before clinical reasoning reduces resistance.
Use the calibrated question: "How can you expect me to prescribe a medication that we just agreed will have no benefit and may harm you?" This puts the burden of reasoning back where it belongs.
Offer the genuine alternative: Effective OTC symptom management, appropriately matched to the patient's symptom profile, is not a consolation prize. It is the appropriate clinical response. Present it as such.
What ZnPaC is — and is not.
ZnPaC is not positioned as a replacement for clinical judgment or a cure for viral URI. It is a 7-day OTC protocol built around four ingredients — zinc, vitamin C, NAC, and quercetin — each with published clinical evidence supporting potential benefit in the setting of a viral URI. Together their effects may be greater than the sum of their parts.
When antibiotics aren't indicated, ZnPaC gives you a safe, evidence-informed plan to hand a patient — not a consolation prize.
"You don't need an antibiotic for a cold. You need a plan."
— Russell W. Raskin, MD